Peptides for Weight Loss: How GLP-1 Compounds Work

Peptides have moved metabolic research into a new era. By acting on the hormonal
signals that govern appetite, blood sugar, and energy use, a small class of compounds has become the
single most-studied tool in modern weight-management science. But “GLP-1” is not one thing — it’s a
family, and the differences between its members matter.

First, what is a peptide?

Peptides are short chains of amino acids — smaller than proteins, but built from the same
building blocks. In the body they act as signalling molecules: they tell cells and
organs what to do and when. Your body makes thousands of them, each tuned to a specific job, from
tissue repair to hormone regulation. For a fuller primer, see the
Complete Peptide Guide.

Synthetic peptides are made in a lab to mimic these natural signals. The weight-loss compounds
below all imitate one or more incretin hormones — the gut signals that coordinate
insulin release, appetite, and the feeling of fullness after a meal.

The GLP-1 family at a glance

GLP-1 (glucagon-like peptide-1) is a natural hormone released after eating. It nudges the body
to release insulin, slows how fast the stomach empties, and signals the brain that you’re full. The
research compounds in this space are grouped by how many of these hormone pathways they
activate — one, two, or three.

Figures reflect published clinical-trial averages
and are presented for research context only. Individual study designs and doses vary.

Single action: semaglutide

Semaglutide is the most familiar GLP-1 receptor agonist. It mimics the GLP-1 hormone directly,
producing three overlapping effects:

• Reduced appetite — it signals the brain to dial down hunger and extend fullness.
• Slower gastric emptying — food leaves the stomach more gradually, so satiety lasts longer.
• Steadier blood sugar — it supports glucose-dependent insulin release.

That delayed digestion is also why early gastrointestinal effects — nausea, bloating — are most
common when a protocol begins, and typically ease as the system adjusts. In trials paired with diet and
activity, semaglutide is associated with roughly 10–15% body-weight reduction on average.

Dual action: tirzepatide

Tirzepatide adds a second target: GIP (glucose-dependent insulinotropic
polypeptide), another incretin hormone involved in insulin sensitivity and energy balance. By engaging
both GLP-1 and GIP receptors, it tends to produce a stronger appetite and metabolic effect than a
single-pathway compound — and, because two pathways are involved, sometimes more pronounced early side
effects. Trial averages land around 15–20% body-weight reduction.

Triple action: retatrutide

Retatrutide is the newest frontier: a triple agonist that targets GLP-1, GIP,
and glucagon receptors at once. The glucagon arm is the novel piece — it’s associated with
increased energy expenditure and fat oxidation, in addition to the appetite and insulin effects of the
other two pathways. Early clinical data point to the largest reductions of the group, up to roughly
22–24% in study settings, though research into optimal dosing is ongoing.

Handling and protocol notes for researchers

These compounds are lyophilized (freeze-dried) powders that must be reconstituted with
bacteriostatic water before study use. A few fundamentals carry over from our handling guide:

• Reconstitute gently — aim the water at the vial wall and swirl; never shake.
• Keep it cold — store reconstituted vials at 2–8 °C, away from light.
• Dose precisely — use the
  Dosage Calculator to convert mg ↔ mcg
  and get an accurate draw.
• Run one variable at a time — single-compound protocols make results interpretable.

Where Quantum fits

Quantum Peptides supplies Retatrutide and Tirzepatide as
Canadian-sourced, third-party-tested research compounds, each with batch-level certificate-of-analysis
documentation. If you’re comparing protocols, the
Personal Roadmap quiz matches compounds to
your stated research goals.